FDA approves anakinra for the treatment of deficiency of IL-1 receptor antagonist (DIRA)

Approval for use in this ultra-rare, autoinflammatory disease caused by a genetic mutation in the IL1RN gene was based on a long-term natural history study including nine patients with DIRA, all of whom achieved inflammatory remission.

Source:

Biospace Inc.